Chemotherapy News and Research

Latest Chemotherapy News and Research

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed.

10 Apr 2013

Research sheds light on malaria-related parasite's transition from acute to chronic stage

A new discovery about the malaria-related parasite Toxoplasma gondii -- which can threaten babies, AIDS patients, the elderly and others with weakened immune function -- may help solve the mystery of how this single-celled parasite establishes life-long infections in people.

10 Apr 2013

New immunotherapies are seldom developed for childhood cancer

More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.

9 Apr 2013

Researchers develop predictive biomarker to identify cancer patients who may respond to autophagy inhibitors

Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation.

9 Apr 2013

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

Research: Paragazole makes triple-negative breast cancer cells express estrogen receptors

Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast cancer cells express estrogen receptors, and that increases the sensitivity of these cells to chemotherapy.

9 Apr 2013

Study: Chicken-killing virus is a promising treatment for prostate cancer

A study at the Virginia-Maryland Regional College of Veterinary Medicine has identified a chicken-killing virus as a promising treatment for prostate cancer in humans.

9 Apr 2013

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

American Society of Hematology announces first recipients of ASH Bridge Grants

The American Society of Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health.

9 Apr 2013

American Cancer Society announces new research, training grants for fiscal year 2013

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013.

9 Apr 2013

Study evaluates efficacy of drug combinations in treating colorectal cancer

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis.

8 Apr 2013

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.

8 Apr 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Berg - a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach - announced today that it will be presenting four abstracts at the AACR Annual Meeting 2013, in Washington, D.C.

8 Apr 2013

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Merrimack Pharmaceuticals, Inc. today announced that one cohort of a Phase 2 non-small cell lung cancer study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

5 Apr 2013

UNC study shows promise for uncovering true mechanisms of human stem cell biology

For the first time, researchers at the University of North Carolina at Chapel Hill have isolated adult stem cells from human intestinal tissue.

5 Apr 2013

Medicare misperceptions create tougher task for lawmakers

The New York Times reports that public misunderstandings about the specifics of entitlement benefits make trimming Medicare spending more difficult. Meanwhile, Politico reports on an idea that might bridge the partisan divide that plagues these efforts.

5 Apr 2013

Wistar scientists describe mechanics of oncogene-induced senescence

Researchers from The Wistar Institute explain a new molecular mechanism behind the phenomenon of oncogene-induced senescence. By depriving the cell of the ability to make new nucleotides-the building blocks of DNA molecules-cells can suppress cancer development by forcing a damaged cell into a senescent state, where the cell remains alive yet cannot reproduce.

5 Apr 2013

First Edition: April 4, 2013

Kaiser Health News staff writer Julie Appleby, working in collaboration with USA Today, reports: "It's not just sore throats and flu shots anymore. Walgreens today became the first retail store chain to expand its health care services to include diagnosing and treating patients for chronic conditions such as asthma, diabetes and high cholesterol. The move is the retail industry's boldest push yet into an area long controlled by physicians, and comes amid continuing concerns about health care costs and a potential shortage of primary care doctors" (Appleby, 4/4).

4 Apr 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Research sheds light on malaria-related parasite's transition from acute to chronic stage

New immunotherapies are seldom developed for childhood cancer

Researchers develop predictive biomarker to identify cancer patients who may respond to autophagy inhibitors

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Research: Paragazole makes triple-negative breast cancer cells express estrogen receptors

Study: Chicken-killing virus is a promising treatment for prostate cancer

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

American Society of Hematology announces first recipients of ASH Bridge Grants

American Cancer Society announces new research, training grants for fiscal year 2013

Study evaluates efficacy of drug combinations in treating colorectal cancer

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

UNC study shows promise for uncovering true mechanisms of human stem cell biology

Medicare misperceptions create tougher task for lawmakers

Wistar scientists describe mechanics of oncogene-induced senescence

First Edition: April 4, 2013

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in